Effectiveness of a closed‐loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: a prospective multicenter real‐life study

Author(s):  
Valentino Cherubini ◽  
Ivana Rabbone ◽  
Maria Giulia Berioli ◽  
Sara Giorda ◽  
Donatella Lo Presti ◽  
...  
2020 ◽  
Author(s):  
Lauren G. Kanapka ◽  
R. Paul Wadwa ◽  
Marc D. Breton ◽  
Katrina J. Ruedy ◽  
Laya Ekhlaspour ◽  
...  

<b>Objective: </b>To further evaluate the safety and efficacy of the Control-IQ closed loop control (CLC) system in children with type 1 diabetes.<b></b> <p><b>Research Design and Methods: </b>Following a 16-week randomized clinical trial (RCT) comparing CLC with sensor augmented pump (SAP) therapy in 101 children age 6 to 13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks. </p> <p><b>Results: </b>In the SAP-CLC cohort, mean percentage of time in range 70-180 mg/dL (TIR) increased from 55±13% using SAP during the RCT to 65±10% using CLC (P<0.001), with 36% of the cohort achieving TIR >70% plus time <54 mg/dL <1% compared with 14% when using SAP (P=0.03). Substantial improvement in TIR was seen after the first day of CLC. Time <70 mg/dL decreased from 1.80% to 1.34% (P<0.001). In the CLC-CLC cohort, mean TIR increased from 53±17% pre-randomization to 67±10% during the RCT and remained reasonably stable at 66±10% through the 12-weeks post-RCT. There were no episodes of diabetic ketoacidosis or severe hypoglycemia in either cohort.</p> <p><b>Conclusions: </b> This further evaluation of the Control-IQ CLC system supports the findings of the preceding RCT that use of a closed-loop system can safely improve glycemic control in children 6 to 13 years old with type 1 diabetes from the first day of use and demonstrates that these improvements can be sustained through 28 weeks of use. </p>


2020 ◽  
Author(s):  
Lauren G. Kanapka ◽  
R. Paul Wadwa ◽  
Marc D. Breton ◽  
Katrina J. Ruedy ◽  
Laya Ekhlaspour ◽  
...  

<b>Objective: </b>To further evaluate the safety and efficacy of the Control-IQ closed loop control (CLC) system in children with type 1 diabetes.<b></b> <p><b>Research Design and Methods: </b>Following a 16-week randomized clinical trial (RCT) comparing CLC with sensor augmented pump (SAP) therapy in 101 children age 6 to 13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks. </p> <p><b>Results: </b>In the SAP-CLC cohort, mean percentage of time in range 70-180 mg/dL (TIR) increased from 55±13% using SAP during the RCT to 65±10% using CLC (P<0.001), with 36% of the cohort achieving TIR >70% plus time <54 mg/dL <1% compared with 14% when using SAP (P=0.03). Substantial improvement in TIR was seen after the first day of CLC. Time <70 mg/dL decreased from 1.80% to 1.34% (P<0.001). In the CLC-CLC cohort, mean TIR increased from 53±17% pre-randomization to 67±10% during the RCT and remained reasonably stable at 66±10% through the 12-weeks post-RCT. There were no episodes of diabetic ketoacidosis or severe hypoglycemia in either cohort.</p> <p><b>Conclusions: </b> This further evaluation of the Control-IQ CLC system supports the findings of the preceding RCT that use of a closed-loop system can safely improve glycemic control in children 6 to 13 years old with type 1 diabetes from the first day of use and demonstrates that these improvements can be sustained through 28 weeks of use. </p>


Diabetes Care ◽  
2020 ◽  
pp. dc201729
Author(s):  
Lauren G. Kanapka ◽  
R. Paul Wadwa ◽  
Marc D. Breton ◽  
Katrina J. Ruedy ◽  
Laya Ekhlaspour ◽  
...  

2017 ◽  
Vol 3 (2) ◽  
pp. 363-366
Author(s):  
Tobias Steege ◽  
Mathias Busek ◽  
Stefan Grünzner ◽  
Andrés Fabían Lasagni ◽  
Frank Sonntag

AbstractTo improve cell vitality, sufficient oxygen supply is an important factor. A deficiency in oxygen is called Hypoxia and can influence for example tumor growth or inflammatory processes. Hypoxia assays are usually performed with the help of animal or static human cell culture models. The main disadvantage of these methods is that the results are hardly transferable to the human physiology. Microfluidic 3D cell cultivation systems for perfused hypoxia assays may overcome this issue since they can mimic the in-vivo situation in the human body much better. Such a Hypoxia-on-a-Chip system was recently developed. The chip system consists of several individually laser-structured layers which are bonded using a hot press or chemical treatment. Oxygen sensing spots are integrated into the system which can be monitored continuously with an optical sensor by means of fluorescence lifetime detection.Hereby presented is the developed hard- and software requiered to control the oxygen content within this microfluidic system. This system forms a closed-loop control system which is parameterized and evaluated.


Author(s):  
Bahram Yaghooti ◽  
Ali Siahi Shadbad ◽  
Kaveh Safavi ◽  
Hassan Salarieh

In this article, an adaptive nonlinear controller is designed to synchronize two uncertain fractional-order chaotic systems using fractional-order sliding mode control. The controller structure and adaptation laws are chosen such that asymptotic stability of the closed-loop control system is guaranteed. The adaptation laws are being calculated from a proper sliding surface using the Lyapunov stability theory. This method guarantees the closed-loop control system robustness against the system uncertainties and external disturbances. Eventually, the presented method is used to synchronize two fractional-order gyro and Duffing systems, and the numerical simulation results demonstrate the effectiveness of this method.


Sign in / Sign up

Export Citation Format

Share Document